Keywords: ph, ii, data, pdl, daclizumab, asthma, protein

Ph II data for PDL's daclizumab in asthma

Article | 22 March 2004

Print This

Protein Design Labs of the USA has reported positive results from a Phase II trial evaluating the use of its ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in